Ramucirumab

Names

[ Name ]:
Ramucirumab

Biological Activity

[Description]:

Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors[1]. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D[2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR

[Target]

VEGFR-2

[References]

[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.

[2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₈₅H₄₃₄N₇₄O₈₈S₂

[ Molecular Weight ]:
6369.07

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.